Monopar Therapeutics (MNPR) Projected to Post Quarterly Earnings on Thursday

Monopar Therapeutics (NASDAQ:MNPR) is projected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Monopar Therapeutics to post earnings of ($0.37) per share for the quarter.

Monopar Therapeutics Stock Performance

NASDAQ MNPR opened at $37.60 on Tuesday. Monopar Therapeutics has a one year low of $1.72 and a one year high of $54.30. The stock has a 50-day moving average of $37.39 and a 200 day moving average of $23.06. The company has a market capitalization of $229.44 million, a price-to-earnings ratio of -19.09 and a beta of 1.18.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on MNPR shares. Piper Sandler reissued an “overweight” rating and set a $76.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, March 19th. HC Wainwright lifted their price objective on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.